Phase 2
N=48
Effects of CLA Supplements on Body Weight and Fat Oxidation
Obesity
Bottom Line
View on ClinicalTrials.gov: NCT00204932 ↗Enrolled (actual)
48
Serious AEs
0.0%
Results posted
Dec 2014
Primary outcome: Primary: Fat Mass — -1.0; 0.7 kg — p=<0.05
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- conjugated linoleic acid (Drug)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Wisconsin, Madison
- Primary completion
- Mar 2005
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Fat Mass |
-1.0; 0.7 | <0.05 sig |
| SECONDARY Total Fat Oxidation |
— | — |
Summary
Conjugated linoleic acid (CLA) is form of fat found in dairy foods, beef and other natural sources. When given to small animals, decreases of body fat have been noted.. Although weight loss is the best treatment for overweight and obesity, it is difficult to maintain the loss in the long term. Because of this, treatment emphasis has turned to small weight losses obtained through non-restrictive diets and prevention of weight regain. This is a study to determine if 6 months of consumption a purified form of CLA will result in greater loss of body fat than control and to determine whether CLA consumption increases total fat oxidation, which would help explain why the weight loss occurs.
Eligibility Criteria
Inclusion Criteria
- BMI 25-29.9 kg/m2
- Absence of a weight change of greater than 3 kg in the previous 6 months
Exclusion Criteria
- Presence of a physical limitation to walking exercise
- Current or recent (6 months) enrollment in a commercial or self-prescribed weight loss program
- A history of metabolic disease-ie. renal, endocrine, hepatic or gastrointestinal disease that would impact the outcome of the study
- A history of a psychiatric or eating disorders Ÿ Presence of metal implants that would interfere with body composition analysis
- Fasting plasma cholesterol >300mg/dl or triglycerides above 500 mg/dl.
- Abnormal EKG
Data sourced from ClinicalTrials.gov (NCT00204932). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.